SCHEMBL296983

SCHEMBL296983

N[C@@H](Cc1c(F)cc(O)cc1F)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 3/20 0.53
ALOX15 P16050 3/20 0.53
HSD17B10 Q99714 3/20 0.53
KDM4E B2RXH2 3/20 0.53
HIF1A Q16665 2/20 0.53
RECQL P46063 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
PKM P14618 2/20 0.53
CYP3A4 P08684 2/20 0.53
NFKB1 P19838 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 2/20 0.53
MAPT P10636 2/20 0.53
BLM P54132 2/20 0.53
PMP22 Q01453 2/20 0.53
KMT2A Q03164 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
RGS12 O14924 1/20 0.53
CYP2C9 P11712 1/20 0.53
CASP1 P29466 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296982 1.00 USP2 (0.53) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL29141540 0.92 USP2 (0.46) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL9847981 0.89 USP2 (0.50) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL9851430 0.87 USP2 (0.45) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL5672308 0.87 USP2 (0.50) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL5672304 0.87 USP2 (0.50) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL28551296 0.87 USP2 (0.50) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL20722991 0.84 USP2 (0.47) USP2ALOX15HSD17B10KDM4EHIF1A
SCHEMBL20722707 0.84 USP2 (0.47) USP2ALOX15HSD17B10KDM4EHIF1A
Hydrochloric Acid SCHEMBL20722737 0.82 USP2 (0.46) USP2ALOX15HSD17B10KDM4EHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025949-A1 Beta-Arrestin Effectors and Compositions and Methods of Use Thereof TREVENA, INC. 2024-01-25 US claimed
WO-2021216529-A1 β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF TREVENA, INC. (US) 2021-10-28 WO claimed
US-20210324005-A1 Beta-Arrestin Effectors and Compositions and Methods of Use Thereof TREVENA, INC. 2021-10-21 US claimed
US-20180016301-A1 Synthesis of Beta-Arrestin Effectors FOREST LABORATORIES HOLDINGS LIMITED (BM) 2018-01-18 US claimed
EP-3145524-A2 SYNTHESIS OF BETA-ARRESTIN EFFECTORS Trevena, Inc. (US) 2017-03-29 EP claimed
EP-2376101-B1 BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF TREVENA INC (US) 2015-12-02 EP claimed
WO-2015179349-A2 SYNTHESIS OF BETA-ARRESTIN EFFECTORS TREVENA, INC. (US) 2015-11-26 WO claimed
US-20150329593-A1 Synthesis of Beta-Arrestin Effectors FOREST LABORATORIES HOLDINGS LIMITED (BM) 2015-11-19 US claimed
US-20150166604-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof TREVENA, INC. 2015-06-18 US claimed
US-8993511-B2 β-arrestin effectors and compositions and methods of use thereof TREVENA, INC. (US) 2015-03-31 US claimed
US-20140357562-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof TREVENA, INC. 2014-12-04 US claimed
US-20140336123-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof TREVENA, INC. 2014-11-13 US claimed
US-8809260-B2 β-arrestin effectors and compositions and methods of use thereof TREVENA, INC. (US) 2014-08-19 US claimed
US-20130274176-A1 BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF TREVENA, INC. (US) 2013-10-17 US claimed
EP-2376101-A2 ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF Trevena, Inc. (US) 2011-10-19 EP claimed
US-20100184701-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof TREVENA, INC. 2010-07-22 US claimed
WO-2010077339-A2 β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF TREVENA, INC. (US) 2010-07-08 WO claimed
EP-4667483-A1 HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE JCR Pharmaceuticals Co., Ltd. (JP) 2025-12-24 EP disclosed
WO-2007065808-A2 NEUROPEPTIDE-2 RECEPTOR-AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-06-14 WO disclosed
US-20070135351-A1 Neuropeptide-2 receptor (Y-2R) agonists and uses thereof CONDE-KNAPE KARIN 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016301-A1 Synthesis of Beta-Arrestin Effectors ARRB1, ADRB1, ADRB3 USP2 1580/4885ALOX15 4560/4885HSD17B10 2629/4885
US-20070135351-A1 Neuropeptide-2 receptor (Y-2R) agonists and uses thereof NPY2R, NPY1R, NPY4R USP2 2739/4885ALOX15 1425/4885HSD17B10 1955/4885
US-20150329593-A1 Synthesis of Beta-Arrestin Effectors ARRB1, ADRB1, ADRB3 USP2 1580/4885ALOX15 4560/4885HSD17B10 2629/4885
US-20140336123-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof ARRB1, ADRB1, ADRB3 USP2 1527/4885ALOX15 3979/4885HSD17B10 2466/4885
US-20150166604-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof ARRB1, ADRB1, ADRB3 USP2 1527/4885ALOX15 3979/4885HSD17B10 2466/4885
US-20210324005-A1 Beta-Arrestin Effectors and Compositions and Methods of Use Thereof ARRB1, ADRB1, FGB USP2 2028/4885ALOX15 3634/4885HSD17B10 3693/4885
US-20130274176-A1 BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF ARRB1, ADRB1, ADRB3 USP2 1527/4885ALOX15 3979/4885HSD17B10 2466/4885
US-20140357562-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof ARRB1, ADRB1, ADRB3 USP2 1527/4885ALOX15 3979/4885HSD17B10 2466/4885
US-20240025949-A1 Beta-Arrestin Effectors and Compositions and Methods of Use Thereof ARRB1, FGB, SARS1 USP2 2017/4885ALOX15 3659/4885HSD17B10 3697/4885
US-20100184701-A1 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof ARRB1, ADRB1, ADRB3 USP2 1527/4885ALOX15 3979/4885HSD17B10 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.